You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Targeted immunotherapy

Showing 1 - 25 of 8,897
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Herpes Simplex Trial in Tokyo (HSVTI Formulation 1, HSVTI Formulation 2, Placebo)

Not yet recruiting
  • Herpes Simplex
  • HSVTI Formulation 1
  • +2 more
  • Tokyo, Japan
    GSK Investigational Site
Aug 4, 2023

Auto/Allo Tandem Transplant for Relapsed B-NHL

Completed
  • Non Hodgkin Lymphoma
  • auto transplant followed by allo transplant
  • (no location specified)
Oct 24, 2022

Hepatocellular Carcinoma, Chemo Effect, Chemotherapeutic Toxicity Trial in Guangzhou (Oxaliplatin,calcium folinic acid,

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
  • +4 more
  • Guangzhou, Guangdong, China
    SUN Yat-sen University Cancer Center
Sep 11, 2023

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • Valhalla, New York
    New York Medical College
Oct 24, 2022

Immunotherapy and Targeted Therapy for Advanced Soft Tissue

Recruiting
  • Advanced Soft Tissue Sarcoma
    • Beijing, Beijing, China
      Department of Medical Oncology, Peking Union Medical College Hos
    Sep 25, 2023

    Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in New York (haplo-identical cells (donor), umbilical cord blood unit

    Recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndrome
    • haplo-identical cells (donor)
    • umbilical cord blood unit (CBU)
    • New York, New York
      Weill Cornell Medical College
    Dec 14, 2022

    Liver Transplantation, Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Lenvatinib, PD-1 inhibitor)

    Not yet recruiting
    • Liver Transplantation
    • Hepatocellular Carcinoma
    • FOLFOX-HAIC
    • +3 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Jul 26, 2022

    Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in Valhalla (DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B)

    Recruiting
    • Non-hodgkin Lymphoma
    • Hodgkin Lymphoma
    • DOC Group B
    • +16 more
    • Valhalla, New York
      New York Medical College
    Jun 9, 2022

    Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

    Not yet recruiting
    • Metastatic Nasopharyngeal Carcinoma
    • +2 more
    • Nivolumab
    • +5 more
    • (no location specified)
    Aug 21, 2023

    Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

    Recruiting
    • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
    • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
    • Shanghai, Shanghai, China
      Shanghai Renji Hospital
    Sep 12, 2023

    T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma Trial (Daratumumab)

    Not yet recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • T-Cell Acute Lymphoblastic Lymphoma
    • (no location specified)
    Jul 13, 2021

    Pancreas Cancer, CAR-T Cell Therapy, Mesothelin Trial in Guangzhou (CAR-T cells)

    Recruiting
    • Pancreas Cancer
    • +3 more
    • CAR-T cells
    • Guangzhou, Guangdong, China
      The Second Affiliated Hospital of Guangzhou Medical University
    Mar 10, 2023

    TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone

    Completed
    • Hepatocellular Carcinoma
    • TACE-HAIC
    • +3 more
    • GuangZhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 8, 2022

    Immunotherapy Among BRAF-Positive Melanoma Patients Treated in

    Completed
    • Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 11, 2022

    Cholangiocarcinoma Trial in Tianjin (GEMOX Regimen, Lenvatinib, Toripalimab)

    Recruiting
    • Cholangiocarcinoma
    • GEMOX Regimen
    • +2 more
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute & Hospital
    Jan 28, 2022

    Glioblastoma Trial in Durham (Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria

    Suspended
    • Glioblastoma
    • Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF
    • +4 more
    • Durham, North Carolina
      Duke University Medical Center
    Aug 16, 2022

    Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

    Recruiting
    • Adenocarcinoma
    • +8 more
    • Radiotherapy targeted to the primary lesion
    • +7 more
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Nov 7, 2023

    Immunotherapy Trial in Xuzhou (CAR-T cell immunotherapy)

    Recruiting
    • Immunotherapy
    • CAR-T cell immunotherapy
    • Xuzhou, Jiangsu, China
      Affiliated Hospital of Xuzhou Medical University
    Apr 26, 2022

    Kidney Cancer, Renal Cell Carcinoma Trial in New Brunswick, New York, Cleveland (Cabozantinib, Nivolumab, Cytoreductive

    Recruiting
    • Kidney Cancer
    • Renal Cell Carcinoma
    • New Brunswick, New Jersey
    • +2 more
    Mar 22, 2022

    Colorectal Cancer Trial in Chongqing (CIK combined with chemo group, CIK combined immunotherapy group, CIK combined targeted

    Recruiting
    • Colorectal Cancer
    • CIK combined with chemotherapy group
    • +3 more
    • Chongqing, Chongqing, China
      Southwest Hospital, Army Medical University (Third Military Medi
    Jan 6, 2023

    Molecular Analysis and Treatment Options of Thymic Malignancies

    Recruiting
    • Thymic Epithelial Tumor
    • +2 more
    • Shanghai, Shanghai, China
      Xiaomin Niu
    Dec 28, 2022

    Molecular Analysis and Treatment Options of SCLC

    Recruiting
    • Small-cell Lung Cancer
    • +4 more
    • Shanghai, China
      Shanghai Chest Hospital
    Jul 6, 2023

    NSCLC Trial in Ghent (Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Dendritic cell immunotherapy
    • +2 more
    • Ghent, Belgium
      Ghent University Hospital
    Dec 23, 2022

    Advanced Cancer, Metastatic Cancer Trial in Shanghai (biological, device, drug)

    Recruiting
    • Advanced Cancer
    • Metastatic Cancer
    • Autologous Adoptive immune cells
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Pudong Medical Center
    Jun 24, 2022

    Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

    Recruiting
    • Non Small Cell Lung Cancer
    • anti-PD-1 or anti-PD-L1
    • +2 more
    • Shanghai, China
      Oncology Department, Shanghai Chest Hospital
    Jul 26, 2022